Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prediction of immune checkpoint inhibitor (ICI) response in non-small cell lung cancer (NSCLC) patients using a microbiome-based biomarker [Abstract]

Autor: Robinson, I., Hochmair, M. J., Jansen, C., Pacifico, C., Sladek, B., Knabl, A., Gasche, N., Absenger, G., Pichler, Martin, Valipour, A.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3341::d1a3d9e3d4a27b9f35ab873cdbe2a8be
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/101555

EP.06E.05 Is Diffusion-Weighted Imaging Able to Indicate Pathological Response in NSCLC after Neo-Adjuvant Immuno-Chemotherapy?

Autor: Kifjak, D., Prosch, H., Hochmair, M., Langs, G., Pochepnia, S., Korajac, A., Heidinger, B.H., Milos, R.-I., Hacker, M., Beer, L.

Publikováno v: Journal of Thoracic Oncology; 2024 Supplement, Vol. 19 Issue 10, pS505-S506, 2p

Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)

Autor: Illini, O., Fabikan, H., Swalduz, A., Krenbek, D., Vikstrom, A., Schumacher, M., Dudnik, E., Studnicka, M., Ohman, R., Wurm, R., Wannesson, L., Peled, N., Kian, W., Bar, J., Daher, S., Addeo, A., Rotem, O., Pall, G., Zer, A., Saad, A., Cufer, T., Sorotsky, H. G., Hashemi, S. M. S., Mohorcic, K., Stoff, R., Rovitsky, Y., Keren-Rosenberg, S., Winder, T., Weinlinger, C., Valipour, A., Hochmair, M. J.

Publikováno v: Illini, O, Fabikan, H, Swalduz, A, Krenbek, D, Vikstrom, A, Schumacher, M, Dudnik, E, Studnicka, M, Ohman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, H G, Hashemi, S M S, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, M J 2022, ' Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP) ', Journal of Thoracic Oncology, vol. 17, no. 9, pp. S460-S460 .
Journal of Thoracic Oncology, 17(9), S460-S460. International Association for the Study of Lung Cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3edf4f818230f06efbece638823d2977
https://research.vumc.nl/en/publications/257aeb33-e1d5-4456-afd1-4318a67e7361

OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)

Autor: Horinouchi, H., Solomon, B.J., Wu, Y.-L., Barlesi, F., Nishio, M., Ahn, J.S., Lee, D.H., Lee, J.-S., Zhong, W., Hochmair, M., Bondarenko, I., Planchard, D., Rittmeyer, A., Ding, B., Ruf, T., Adler, L., Scalori, A., Dziadziuszko, R.

Publikováno v: In Journal of Thoracic Oncology October 2024 19(10) Supplement:S39-S39